| Test Name and Number | Recommended Use | Limitations | Follow Up |
|---|
| Leukemia/Lymphoma Phenotyping (Comprehensive-Whole Blood) 0096299 Method: Flow Cytometry
|
Use for whole blood specimens to aid in selection of appropriate therapy and assessment of clinical behavior and prognosis
Available antigens included:
T-cell: CD1, CD2, CD3, CD4, CD5, CD7, CD8, TCR alpha-beta, TCR gamma-delta, Cytoplasmic CD3
B-cell: CD10, CD19, CD20, CD22, CD23, CD24, CD79b, CD103, Kappa, Lambda, FMC7, Cytoplasmic Kappa, Cytoplasmic Lambda
Myelo/Mono: CD11b, CD13, CD14 (Mo2), CD14 (MY4), CD15, CD33, CD64, CD117, myeloperoxidase
Misc: CD11c, CD16, CD25, CD30, CD34, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, HLA-DR, glycophorin, TdT, bcl-2
| | |
| Leukemia/Lymphoma Phenotyping (Comprehensive - Bone Marrow) 0095244 Method: Flow Cytometry
|
Use for bone marrow specimens to aid in selection of appropriate therapy and assessment of clinical behavior and prognosis
Available antigens included:
T-cell: CD1, CD2, CD3, CD4, CD5, CD7, CD8, TCR alpha-beta, TCR gamma-delta, Cytoplasmic CD3
B-cell: CD10, CD19, CD20, CD22, CD23, CD24, CD79b, CD103, Kappa, Lambda, FMC7, Cytoplasmic Kappa, Cytoplasmic Lambda
Myelo/Mono: CD11b, CD13, CD14 (Mo2), CD14 (MY4), CD15, CD33, CD64, CD117, myeloperoxidase
Misc: CD11c, CD16, CD25, CD30, CD34, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, HLA-DR, glycophorin, TdT, bcl-2
| | |
| T-Cell Clonality by Flow Cytometry Analysis of TCR V-Beta 0093199 Method: Flow Cytometry
|
Further characterize phenotypically abnormal T-cell populations identified by flow cytometry
Determine the existence of monoclonality based on expression of T-cell antigen receptor beta chain variable regions (TCR V-Beta)
| Tests only for T-cell alpha and beta antigen receptors; if T-cell delta or gamma antigen receptors testing is desired, PCR testing is recommended | |
| T-Cell Clonality Screening Assay by PCR, Fluid 0055567 Method: Polymerase Chain Reaction/Fragment Analysis
|
Determine presence of a monoclonal T-cell population in whole blood or bone marrow
| A negative result does not entirely exclude the presence of a T-cell receptor gamma rearrangement (or monoclonal T-cell population) in the sample |
Confirm results with T-cell clonality assessment by restriction fragment souther blot hybridization, fluid
|
| T-Cell Clonality Screening Assay by PCR, Tissue 0055568 Method: Polymerase Chain Reaction/Fragment Analysis
|
Determine presence of a monoclonal T-cell population in tissue
| A negative result does not entirely exclude the presence of a T-cell receptor gamma gene rearrangement (or monoclonal T-cell population) in the sample |
Confirm results with T-cell clonality assessment by restriction fragment souther blot hybridization, fluid
|
| T-Cell Clonality Assessment by Restriction Fragment-Southern Blot Hybridization, Tissue 0055594 Method: Restriction Fragment Southern Blot Hybridization
|
Confirm presence of T-cell receptor beta gene arrangement presence in tissue
| A negative result does not entirely exclude the presence of a T-cell receptor gene rearrangement (or monoclonal T-cell population) in the sample | |
| T-Cell Clonality Assessment by Restriction Fragment-Southern Blot Hybridization, Fluid 0055596 Method: Restriction Fragment Southern Blot Hybridization
|
Confirm presence of T-cell receptor beta gene arrangement presence in whole blood or bone marrow
| A negative result does not entirely exclude the presence of a T-cell receptor gene rearrangement (or monoclonal T-cell population) in the sample | |
| bcl-2/JH, t(14;18) Translocation by PCR, Fluid 0055616 Method: Polymerase Chain Reaction
|
Detect chromosomal translocation t(14:18) (bcl/2/IGH gene rearrangements) [bcl-2/JH]
Components include BCL2/IGH, t(14;18) [bcl-2/JH] translocation major breakpoint region (MBR), and BCL2/IGH, t(14;18) [bcl-2/JH] translocation minor cluster region, (MCR)
| A negative result does not entirely exclude the presence of a BCL2/IGH [bcl-2/JH] chromosomal t(14;18) translocation | |
| bcl-2/JH, t(14;18) Translocation by PCR, Tissue 0055619 Method: Polymerase Chain Reaction
|
Use to determine presence of BCL2/IGH t(14;18) [bcl-2/JH] chromosomal translocation (non-Hodkins lymphoma)
Components include BCL2/IGH, t(14;18) [bcl-2/JH] translocation major breakpoint region (MBR) and BCL2/IGH, t(14;18) [bcl-2/JH] translocation minor cluster region (MCR)
| A negative result does not entirely exclude the presence of a BCL2/IGH [bcl-2/JH] chromosomal t(14;18) translocation | |
| Chromosome Analysis, FISH-Interphase 0092615 Method: Fluorescence in situ Hybridization
|
FISH probes must be specified and include c-MYC rearrangements, t(11;14) (IGH/CCND1), t(14;18)(IGH/BCL2), IGH rearrangement with unknown partner, ALK rearrangements, and BCL6 rearrangements
Fresh tissue sample required
| | |
| ZAP-70 Analysis by Flow Cytometry 0092392 Method: Flow Cytometry
|
Assist in the clinical management of patients with established diagnoses of chronic lymphocytic leukemia
| ZAP-70 results should not be used for diagnostic purposes Results of this test should always be correlated with morphologic and clinical information | |
| Chromosome Analysis, Chronic Lymphocytic Leukemia (CLL) Panel by FISH 0092616 Method: Fluorescence in situ Hybridization
|
Fluorescence in situ hybridization panel is performed for CLL prognosis
Specific genomic abnormalities tested for are: ATM, D13S25, p53, and trisomy 12
| Limit of detection is probe dependent and around 1-5% in interphase nuclei |
Repeat testing as clinically indicated to monitor disease progression
|
| Chromosome Analysis, Bone Marrow 0097605 Method: Giemsa-Band Analysis
|
Detect chromosome abnormalities associated with lymphoproliferative disorders in bone marrow
| |
Repeat testing as clinically indicated to monitor disease progression
|
| t(11;14) IgH-CCND1 Translocation by FISH 0049381 Method: Fluorescence in situ Hybridization
|
Assist in the clinical management of patients with established diagnoses of mantle cell lymphoma
Fixed tissue sample required
| | |
| bcl-1/JH, t(11;14) Translocation by PCR, Fluid 0055557 Method: Polymerase Chain Reaction
|
Assist in the clinical management of patients with established diagnoses of mantle cell lymphoma
Detect CCND1/IGH, t(11,14) [bcl-1/JH] translocation
| A negative result does not entirely exclude the presence of a CCND1/IGH [bcl-1/JH] chromosomal t(11;14) translocation | |
| Immunohistochemistry Stain Offering arup005 Method: Immunohistochemistry
|
For fixed tissue samples, diagnostic consultative services as well as immunohistochemical staining for ALK-1, BCL-2, BCL-6, Beta F-1, BOB.1, BAX, CD!a, CD2 (LFA-2), CD3, CD4 (4B12), CD5, CD7 CD8, CD10, CD15 (Leu M1), CD20 (L26), CD21, CD22 (BL-CAM), CD23, CD25, CD30, CD34, CD42b, CD43 (L60), CD44 (HCAM), CD45 (LCA), CD45R (4KB5), CD45RO (UCHL-1), CD56, CD57, CD61 (gpIIIA), CD74 (LN1), CD79a, CD95, CD99 (013), CD117, CD138 (sydican-1), Caspase3, c-Myc, Cyclin D1 (BCL-a), D2-40, DBA-44, Fascin, Fli-1, glycophorin A, kappa, lambda, Muc-1, myeloperoxidase, Oct-2, p80, PAX-5, Rb1, TIA-1, TRAP and TdT are available
| | |